Loading…
Employees: 1,078
Size Beijing Chunlizhengda Medical Instruments (688236.SS) is a China Health Care company (Medical Specialties) with a market value of $684M, the 3115th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.60 on 6 Nov 2026.
Performance Over six months the shares fell 21.4%, against -9.1% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 13.1% over the last twelve months (peer median +9.3%); the operating margin is 30.6% (peer median 12.6%).
Valuation It trades at 19.1× forward earnings against a peer median of 24.1× (7th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.5 points above its cost of capital (8.1% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥916M | CN¥1.04B | CN¥800M | CN¥1.20B | CN¥1.19B |
| Revenue growth | — | +30% | -33% | 0% | — |
| Gross profit | CN¥600M | CN¥657M | CN¥508M | CN¥842M | CN¥886M |
| EBITDA | n/a | CN¥308M | CN¥125M | CN¥292M | CN¥307M |
| Net income | CN¥270M | CN¥273M | CN¥125M | CN¥278M | CN¥308M |
| Free cash flow | CN¥322M | CN¥361M | -CN¥30.4M | CN¥501M | CN¥43.3M |
| Capital expenditure | CN¥42.2M | CN¥59.1M | CN¥49.2M | CN¥33.2M | CN¥24.9M |
| Total debt | CN¥2.39M | CN¥3.78M | CN¥919,036 | CN¥12.8M | CN¥18.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688236.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.2% | -1.4% | 8th lowest of 21 |
| 6-month return | -21.4% | -9.1% | 5th lowest of 21 |
| Distance from 52-week high | -54.2% | -31.3% | 4th lowest of 21 |
| Revenue growth (TTM) | -13.1% | +9.3% | 5th lowest of 21 |
| Operating margin | 30.6% | 12.6% | 3rd highest of 21 |
| Forward P/E | 19.1× | 24.1× | 7th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -5.4% | 8.1% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +2.2% | +13.3% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | -7.6 pp | -9.2 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | +16.5 pp | +2.5 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 19.1× | -5.4% | +2.2% |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |